Elliott Crouser, MD
Professor
Internal Medicine
Academic contact
473 W 12th Ave
Columbus, OH 43210-1252
Phone: 614-346-6690
Fax: 614-293-5503
Academic information
- Department: Internal Medicine
- Division: Pulmonary, Critical Care and Sleep
Research interests
- Critical Care
- Sarcoidosis
About
Biography
In addition to my clinical responsibilities, I serve as a professor of Internal Medicine at The Ohio State University College of Medicine, where I am dedicated to advancing research and education in pulmonary and critical care medicine.
Credentials
Education
- Fellowship - Pulmonary Disease
-
Ohio State University Wexner Medical Center, Columbus, OH, United States
7/1/1992 - 6/1/1996 - Residency - Internal Medicine
-
Ohio State University Wexner Medical Center, Columbus, OH, United States
7/1/1990 - 6/1/1992 - Internship - Internal Medicine
-
Ohio State University Wexner Medical Center, Columbus, OH, United States
6/1/1989 - 6/1/1990 - Doctor of Medicine (MD)
-
University of Toledo College of Medicine, Toledo, OH
8/1/1985 - 6/30/1989
Certifications
-
American Heart Association National Center
8/30/2024 -
American Board of Internal Medicine/Critical Care Medicine
11/9/1995 -
American Board of Internal Medicine/Pulmonary Disease
11/10/1994
Research
Research interests
- Critical Care
- Sarcoidosis
Additional Research Interests
Critical Care Research themes:
- Mitochondrial mechanisms of organ failure during sepsis
- Biomarkers for the early detection of sepsis in the hospital setting; particularly the monocyte distribution width (MDW), FDA approved (2020) for the detection of sepsis in adults admitted to the Emergency Department
Sarcoidosis Research themes:
- Genomic studies of granulomas to determine disease mechanisms and to identify novel therapeutic targets
- Clinical practice guidelines for the diagnosis and management of sarcoidosis
- We established the first tractable laboratory disease model
Current Research
- We are establishing novel biomarkers for early sepsis detection based on machine learning and employing the electronic medical record in conjunction with the US Government and FDA
- We are investigating novel therapies for COVID-induced acute lung injury
- We are conducting translational research in the field of pulmonary sarcoidosis to elicit disease mechanisms, establish novel biomarkers and to investigate novel therapies.
Awards and Honors
- AOA, 1989
- Professor of Medicine with Tenure, 2016
- Star Research Awards, Society of Critical Care Medicine: 2017, 2019
- Chair, Scientific Advisory Board; Foundation for Sarcoidosis Research 2021
- President, Americas Association of Sarcoidosis and Other Granulomatous Disorders (AASOG) 2018-2020
- Chair, American Thoracic Society Official Clinical Practice Guidelines for Sarcoidosis: 2017-2020
- Chair, Internal Medicine Section (>4000 members); Society of Critical Care Medicine: 2019-2021
Active Funding
NIH/NIAID/UO1; 2022-2026:
Supplemental Citacoline Administration for Reducton of Lung Injury Efficacy Trial (SCARLET).
Multi-PIs- Crouser, Davis
Health and Human Services/BARDA/Beckman Coulter; 2020-2025:
Sepsis Early Warning Algorithm.
PI-Crouser
(pending) NIH/NIAID/R21; 12/2022-11/2024:
Role of Renin-Angiotensin-Aldosterone System during sarcoidosis granuloma formation.
PI- Crouser (impact score 17; pay line 2022 = impact score 28)
(pending) NIH/NHLBI/RO1:
Molecular Characterization of Progressive Pulmonary Sarcoidosis.
Multi-PIs: Crouser, Maier, Bhargava (Percentile score 15; payline 2022 = 15%)
Industry Research Contracts using Dr. Crouser’s proprietary in vitro sarcoidosis model to identify novel therapeutic targets, biomarkers and related disease mechanisms:
- aTyr Pharmaceutical
- Xentria Pharmaceutical
- Star-Therapeutics Pharmaceutical
- 23 & ME
- Palleon Pharmaceutical